A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 6, 2024

Study Completion Date

May 31, 2025

Conditions
Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicPatient Preference
Interventions
DRUG

Subcutaneous azacitidine

Subcutaneous azacitidine, 75mg/m2, 7 days

DRUG

Oral decitabine/cedazuridine

Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days

Trial Locations (11)

Unknown

Calvary Mater Newcastle, Newcastle

Pindara Private Hospital, Benowa

Townsville Hospital, Townsville

Adelaide Oncology and Haematology, North Adelaide

Grampian Health (Ballarat Base Hospital), Ballarat Central

Latrobe Regional Hospital, Traralgon

Christchurch Hospital, Christchurch

Dunedin Hospital, Dunedin

Auckland City Hospital, Grafton

Waikato Hospital, Hamilton

North Shore Hospital (Waitemata District Health Board), Takapuna

All Listed Sponsors
lead

Otsuka Australia Pharmaceutical Pty Ltd

INDUSTRY

NCT05883956 - A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia | Biotech Hunter | Biotech Hunter